GALT - Galectin Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
0
0
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
4,865
6,471
11,721
15,325
13,114
Selling General and Administrative
6,187
7,131
4,526
6,156
6,965
Total Operating Expenses
11,052
13,602
16,247
21,481
20,079
Operating Income or Loss
-11,052
-13,602
-16,247
-21,481
-20,079
Interest Expense
210
336
12
-
-
Total Other Income/Expenses Net
-
-
-
0
0
Income Before Tax
-11,175
-13,900
-16,235
-21,436
-20,027
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-11,175
-13,900
-16,235
-21,436
-20,027
Net Income
-11,175
-13,900
-16,235
-21,436
-20,027
Net Income available to common shareholders
-18,554
-15,047
-17,467
-22,350
-21,124
Reported EPS
Basic
-
-0.38
-0.49
-0.76
-0.88
Diluted
-
-0.38
-0.49
-0.76
-0.88
Weighted average shares outstanding
Basic
-
39,414
35,521
29,216
24,120
Diluted
-
39,414
35,521
29,216
24,120
EBITDA
-
-13,564
-16,222
-21,474
-20,072